Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Tyrosine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 known ✓ | P03372 | 1/20 | 0.53 |
| ▸ | ESR2 known ✓ | Q92731 | 1/20 | 0.53 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.53 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.92 |
| ▸ | PTGS1 | P23219 | 3/20 | 0.66 |
| ▸ | ALPI | P09923 | 1/20 | 0.66 |
| ▸ | PKM | P14618 | 1/20 | 0.66 |
| ▸ | XIAP | P98170 | 1/20 | 0.66 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.61 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.61 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | USP2 | O75604 | 1/20 | 0.61 |
| ▸ | EGFR | P00533 | 1/20 | 0.61 |
| ▸ | LCK | P06239 | 1/20 | 0.61 |
| ▸ | FYN | P06241 | 1/20 | 0.61 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
| ▸ | RECQL | P46063 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tyrosine SCHEMBL28270669 | 1.00 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL6374042 | 1.00 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL28297995 | 1.00 | SLC7A5 (0.92) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL25296443 | 0.98 | SLC7A5 (0.89) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL638520 | 0.96 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL11676367 | 0.96 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL1581 | 0.96 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL11520041 | 0.96 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL11676395 | 0.96 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP | |
| Tyrosine SCHEMBL1580 | 0.96 | SLC7A5 (1.00) | SLC7A5PTGS1ALPIPKMXIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108752224-B | Preparation method of lysine acetate bulk drug | 无锡晶海氨基酸股份有限公司 | 2021-03-02 | — | — | CN | disclosed |
| CN-108752224-A | A kind of preparation method of Lysine Acetate bulk pharmaceutical chemicals | 无锡晶海氨基酸股份有限公司 | 2018-11-06 | — | — | CN | disclosed |
| CN-106420554-A | Anti-hair-loss nutrient liquid | 拉芳家化股份有限公司 | 2017-02-22 | — | — | CN | disclosed |
| CN-104829477-A | Preparation method of bulk drug of lysine acetate | WUXI JINGHAI AMINO ACID CO LTD | 2015-08-12 | — | — | CN | disclosed |
| EP-1575900-A4 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LT (AU) | 2007-02-21 | — | — | EP | disclosed |
| US-20050245432-A1 | N-methyl amino acids | UBIQUITOUS TECHNOLOGIES PTY. LTD. (AU) | 2005-11-03 | — | — | US | disclosed |
| EP-1575900-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2005-09-21 | — | — | EP | disclosed |
| US-6784283-B2 | ACTIVE MATERIALS FOR GRAMPOSITIVE BACTERIA, ANTIBIOTIC RESISTANCE INFECTIONS | THE UNIVERSITY OF BRITISH COLUMBIA (GB) | 2004-08-31 | — | — | US | disclosed |
| WO-2004007427-A1 | N-METHYL AMINO ACIDS | UBIQUITOUS TECHNOLOGIES PTY LTD (AU) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245432-A1 | N-methyl amino acids | VIP, NPPA, PTMS | ESR1 3494/4885ESR2 2271/4885ADRA2A 3381/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.